半岛bd体育手机客户端
描述
Spartalizumab (anti-PD-1)是一种针对PD-1的人源IgG4抗体，抑制PD-L1和PD-L2与PD-1的结合。PDR001可与PD-1以高亲和力结合，抑制其生物活性；MW: 145.8 KD。
体内活性
In phase 1/2 studies, PDR001 has a manageable safety profile and preliminary antitumor activity in advanced solid tumors[1].
m.cnreagent.com